Simvastatin Blunts Endotoxin-Induced Tissue Factor In Vivo

Sabine Steiner(Helmholtz Munich), Christoph Kopp(Friedrich-Alexander-Universität Erlangen-Nürnberg), Johannes Pleiner(Wilhelminen Hospital), Johann Wojta(Medical University of Vienna), Daniela Seidinger(Wilhelminen Hospital), Michael Wolzt(University of California System), Kurt Huber(Sigmund Freud Privatuniversität Wien), Christoph Kaun(University of Vienna), Walter S. Speidl(University of Applied Sciences St Pölten), Erich Minar(Medical University of Vienna), Gerlinde Zorn(Wilhelminen Hospital)
Circulation
April 11, 2005
10.1161/01.cir.0000158665.27783.0c
Cited by 146

Related Papers

ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
|European Heart Journal|2012|6.8k
Balloon Angioplasty versus Implantation of Nitinol Stents in the Superficial Femoral Artery
|New England Journal of Medicine|2006|1.2k
Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation
|Circulation|2011|1.1k
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial
|The Lancet|2018|793
High Plasma Levels of Factor VIII and the Risk of Recurrent Venous Thromboembolism
|New England Journal of Medicine|2000|765